Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.77 |
| ▸ | MAPT | P10636 | 5/20 | 0.77 |
| ▸ | THRB | P10828 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 4/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.77 |
| ▸ | HTT | P42858 | 3/20 | 0.77 |
| ▸ | TP53 | P04637 | 3/20 | 0.77 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.77 |
| ▸ | RECQL | P46063 | 2/20 | 0.77 |
| ▸ | BLM | P54132 | 2/20 | 0.77 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.77 |
| ▸ | TSHR | P16473 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | EGFR | P00533 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexamethyl Pararosaniline SCHEMBL94116 | 0.89 | TDP1 (0.96) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| Hexamethyl Pararosaniline SCHEMBL9171 | 0.88 | TDP1 (1.00) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL12459725 | 0.85 | TDP1 (0.54) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL15298104 | 0.85 | TDP1 (0.71) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL18252758 | 0.84 | MEN1 (0.53) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL14310873 | 0.83 | TDP1 (0.84) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| Brilliant Green SCHEMBL171205 | 0.83 | TDP1 (0.84) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL12066678 | 0.82 | TDP1 (0.51) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL171347 | 0.82 | MAPK1 (0.82) | TDP1MAPK1KMT2ASMN1; SMN2MAPT | |
| Brilliant Green SCHEMBL28216 | 0.82 | TDP1 (0.88) | TDP1MAPK1KMT2ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025070375-A1 | METHOD FOR SUPPRESSING IMMUNOREACTION | 株式会社ナノエッグ | 2025-04-03 | — | — | WO | claimed |
| EP-4204503-B1 | PEELABLE WRITING INK COMPOSITION WITH COLOR-CHANGING FOR WRITING POROUS SUBSTRATES | SOCIéTé BIC (FR) | 2024-09-25 | — | — | EP | claimed |
| EP-4204503-A1 | PEELABLE WRITING INK COMPOSITION WITH COLOR-CHANGING FOR WRITING POROUS SUBSTRATES | Société BIC (FR) | 2023-07-05 | — | — | EP | claimed |
| US-20230203332-A1 | PEELABLE INK COMPOSITION WITH COLOR-CHANGING FOR POROUS SUBSTRATES | SOCIéTé BIC (FR) | 2023-06-29 | — | — | US | claimed |
| EP-3889226-B1 | PEELABLE INK COMPOSITION WITH COLOR-CHANGING FOR POROUS SUBSTRATES | SOCIéTé BIC (FR) | 2022-11-30 | — | — | EP | claimed |
| WO-2022043560-A1 | PEELABLE WRITING INK COMPOSITION WITH COLOR-CHANGING FOR WRITING POROUS SUBSTRATES | SOCIETE BIC (FR) | 2022-03-03 | — | — | WO | claimed |
| EP-4748578-A1 | INK CARTRIDGE | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2026-05-27 | — | — | EP | disclosed |
| EP-4748577-A1 | STORAGE BAG | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2026-05-27 | — | — | EP | disclosed |
| US-12617959-B2 | Peelable ink composition for non-porous substrates | SOCIéTé BIC (FR) | 2026-05-05 | — | — | US | disclosed |
| US-12617960-B2 | Washable ink composition | SOCIéTé BIC (FR) | 2026-05-05 | — | — | US | disclosed |
| EP-4328248-B1 | ULTRAVIOLET-CURABLE WATER-BASED INK, DISPERSION, ULTRAVIOLET-CURABLE WATER-BASED COMPOSITION AND PRINTED MATTER | MITSUBISHI CHEM CORP (JP) | 2026-03-18 | — | — | EP | disclosed |
| EP-4711424-A1 | AQUEOUS INK COMPOSITION FOR WRITING UTENSILS, AND WRITING UTENSIL OBTAINED USING SAME | MITSUBISHI PENCIL COMPANY, LIMITED (JP) | 2026-03-18 | — | — | EP | disclosed |
| US-20260061771-A1 | MULTI-CORE WRITING IMPLEMENT | PILOT CORPORATION KK (JP) | 2026-03-05 | — | — | US | disclosed |
| WO-2011091413-A1 | METHOD AND DOSAGE FORM TO CONFIRM COMPLIANT USE OF A BIOACTIVE AGENT | FUISZ RICHARD C (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110182827-A1 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent | FUISZ RICHARD C | 2011-07-28 | — | — | US | disclosed |
| US-20110182807-A1 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent | FUISZ RICHARD C | 2011-07-28 | — | — | US | disclosed |
| US-20110182824-A1 | METHOD AND DOSAGE FORM TO CONFIRM COMPLIANT USE OF A BIOACTIVE AGENT | FUISZ RICHARD C | 2011-07-28 | — | — | US | disclosed |
| US-20110182824-A1 | METHOD AND DOSAGE FORM TO CONFIRM COMPLIANT USE OF A BIOACTIVE AGENT | FUISZ RICHARD C | 2011-07-28 | — | — | US | disclosed |
| WO-2011084803-A2 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | LIVING PROOF, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110182827-A1 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent | BMP6, GUSB, SI | TDP1 3459/4885MAPK1 3249/4885KMT2A 3757/4885 |
| US-12617960-B2 | Washable ink composition | WASHC5, PGD, FTO | TDP1 2519/4885MAPK1 1451/4885KMT2A 419/4885 |
| US-12617959-B2 | Peelable ink composition for non-porous substrates | FLNB, NUCB2, DYRK1B | TDP1 275/4885MAPK1 1850/4885KMT2A 3924/4885 |
| US-20110154583-A1 | COLORING AGENTS AND METHODS OF USE THEREOF | MPO, HLA-C, ADH7 | TDP1 841/4885MAPK1 3478/4885KMT2A 1622/4885 |
| US-20260061771-A1 | MULTI-CORE WRITING IMPLEMENT | TYR, PIK3C3, PRKDC | TDP1 935/4885MAPK1 1116/4885KMT2A 1373/4885 |
| US-20110182807-A1 | Method and Dosage Form to Confirm Compliant Use of a Bioactive Agent | BMP6, ALPG, BMP2 | TDP1 4474/4885MAPK1 3341/4885KMT2A 4798/4885 |
| US-20110182824-A1 | METHOD AND DOSAGE FORM TO CONFIRM COMPLIANT USE OF A BIOACTIVE AGENT | BMP6, GUSB, BMP2 | TDP1 3987/4885MAPK1 3556/4885KMT2A 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.